The impact of HMG-CoA reductase inhibitors use on the clinical outcomes in critically ill patients with COVID-19: A multicenter, cohort study

• Main Authors: Khalid Al Sulaiman (Author), Ohoud Aljuhani (Author), Ghazwa B. Korayem (Author), Ali F. Altebainawi (Author), Shmeylan Al Harbi (Author), Abdulrahman Al Shaya (Author), Hisham A. Badreldin (Author), Raed Kensara (Author), Abdullah F. Alharthi (Author), Jahad Alghamdi (Author), Ahad Alawad (Author), Rand Alotaibi (Author), Abdullah Kharbosh (Author), Hessa Al Muqati (Author), Abdulmohsen Alhuwahmel (Author), Mohammed Almusallam (Author), Ghada Albarrak (Author), Ibrahim Al Sulaihim (Author), Bader Alanazi (Author), Bodoor S. Al-Dosari (Author), Ramesh Vishwakarma (Author), Alawi S. Alsaeedi (Author), Ghassan Al Ghamdi (Author), Hadeel Alkofide (Author), Hasan M. Al-Dorzi (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundThe cardiovascular complications of Coronavirus Disease 2019 (COVID-19) may be attributed to the hyperinflammatory state leading to increased mortality in patients with COVID-19. HMG-CoA Reductase Inhibitors (statins) are known to have pleiotropic and anti-inflammatory effects and may have...